

Yanxia Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4988093/publications.pdf>

Version: 2024-02-01

45
papers

768
citations

567281

15
h-index

580821

25
g-index

46
all docs

46
docs citations

46
times ranked

949
citing authors

#	ARTICLE	IF	CITATIONS
1	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 43-51.	7.0	125
2	Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1904-1909.	30.7	65
3	Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1296-305.	7.1	59
4	Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. <i>Cancer Science</i> , 2012, 103, 1679-1687.	3.9	48
5	The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. <i>International Journal of Oncology</i> , 2014, 44, 735-744.	3.3	47
6	Patient-Derived Organoids Can Guide Personalized Therapies for Patients with Advanced Breast Cancer. <i>Advanced Science</i> , 2021, 8, e2101176.	11.2	42
7	An assessment of prognostic immunity markers in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 35.	5.2	41
8	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. <i>Cancer Biology and Medicine</i> , 2020, 17, 896-909.	3.0	35
9	CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer. <i>Cancer Letters</i> , 2019, 447, 130-140.	7.2	32
10	Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>BioDrugs</i> , 2019, 33, 357-371.	4.6	23
11	RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4520-4520.	1.6	23
12	Integrative Comparison of mRNA Expression Patterns in Breast Cancers from Caucasian and Asian Americans with Implications for Precision Medicine. <i>Cancer Research</i> , 2017, 77, 423-433.	0.9	20
13	Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature. <i>Cancer</i> , 2020, 126, 3837-3846.	4.1	20
14	The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 55-62.	6.3	19
15	Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis. <i>BioDrugs</i> , 2019, 33, 373-389.	4.6	18
16	Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer. <i>Oncologist</i> , 2020, 25, 21-e15.	3.7	17
17	A Novel Ferroptosis-Related Gene Signature Predicts Overall Survival of Breast Cancer Patients. <i>Biology</i> , 2021, 10, 151.	2.8	17
18	An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4584-4584.	1.6	16

#	ARTICLE	IF	CITATIONS
19	Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. <i>Cancer Communications</i> , 2021, 41, 171-182.	9.2	15
20	Impact of diabetes on promoting the growth of breast cancer. <i>Cancer Communications</i> , 2021, 41, 414-431.	9.2	12
21	Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center. <i>Cancer Communications</i> , 2020, 40, 222-233.	9.2	11
22	Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1003-1003.	1.6	10
23	Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 619-628.	2.5	9
24	Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone. <i>BMC Cancer</i> , 2021, 21, 919.	2.6	7
25	Treatment Outcome of Different Chemotherapy in Patients With Relapsed or Metastatic Malignant Urachal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 739134.	2.8	5
26	High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199343.	3.2	5
27	Oxaliplatin, fluorouracil and leucovorin (FOLFOX) as first-line chemotherapy for metastatic or recurrent colorectal cancer patients. <i>Chinese Journal of Clinical Oncology</i> , 2007, 4, 397-400.	0.0	4
28	Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy—A systematic review and meta-analysis. <i>Clinical Immunology</i> , 2022, 236, 108927.	3.2	4
29	Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience. <i>Oncotarget</i> , 2016, 7, 63722-63729.	1.8	2
30	Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0148849.	2.5	2
31	Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 197-209.	2.5	2
32	Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2020, 25, e1439-e1445.	3.7	2
33	A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy. <i>Oncologist</i> , 2021, 26, e742-e748.	3.7	2
34	Postponing tumor onset and tumor progression can be achieved by alteration of local tumor immunity. <i>Cancer Cell International</i> , 2021, 21, 97.	4.1	2
35	Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1-Based Therapy. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 621883.	3.5	2
36	Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy. <i>Translational Cancer Research</i> , 2020, 9, 1225-1234.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.. Journal of Clinical Oncology, 2021, 39, 1042-1042.	1.6	1
38	Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study.. Journal of Clinical Oncology, 2021, 39, 521-521.	1.6	1
39	Authorâ€™s Reply to PuÃ©rtolas-Tena and PÃ©rez-Surio: â€œEfficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysisâ€. BioDrugs, 2019, 33, 585-588.	4.6	0
40	Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies in a real-world setting.. Journal of Clinical Oncology, 2021, 39, e24072-e24072.	1.6	0
41	Incidence of neutropenia in breast cancer patients with administration of mecapegfilgrastim.. Journal of Clinical Oncology, 2021, 39, e24070-e24070.	1.6	0
42	Endocrine treatment-related symptoms and outcomes in breast cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2016, 34, e12001-e12001.	1.6	0
43	Fulvestrant as maintenance therapy after first-line chemotherapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer (FANCY), a prospective, multicenter, single arm phase 2 study.. Journal of Clinical Oncology, 2017, 35, 1066-1066.	1.6	0
44	Abstract P1-16-02: A randomized phase II study investigating oral metronomic vinorelbine versus conventional dosage of vinorelbine in HER2-negative metastatic breast cancer previously treated with anthracycline or taxane:clinical results and biomarker analysis. Cancer Research, 2022, 82, P1-16-02-P1-16-02.	0.9	0
45	The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005). BMC Cancer, 2022, 22, 271.	2.6	0